Gilead Sciences, Inc. (GILD) gains on deep earnings beat analysis
Gilead Sciences, Inc. (GILD) gains after a stronger-than-expected earnings report, but the real story is deeper than the headline beat. This analysis breaks down revenue momentum, HIV and Yeztugo growth, acquisition-related charges, and what the latest guidance means for the stock.
Gilead Sciences (GILD) reported a deeper-than-expected earnings beat, with revenue of $7.80 billion topping estimates and EPS coming in better than forecast despite a reported quarterly loss. Investors responded positively because HIV sales remain strong, Yeztugo is scaling quickly, and management raised its 2026 HIV growth outlook to about 8%.
Gilead Sciences, Inc. (GILD) gains after earnings beat
Gilead Sciences, Inc. (GILD) delivered a stronger-than-expected earnings result, with EPS of -$6.75 versus an estimated -$7.26 and revenue of $7.80B versus a $7.40B consensus. GILD shares posted gains of 3.13% to $135.25 at the last regular-session close, while trading volume reached 10,078,462 shares against a 7,612,335 average.
Key Takeaways
Gilead beat on both reported EPS and revenue. EPS came in at -$6.75 versus -$7.26 expected, while revenue reached $7.80B versus $7.40B expected.
HIV remains the central growth engine. The preceding quarter produced $5.0B in HIV sales, up 10% year over year, led by Biktarvy, Descovy and Yeztugo.
Yeztugo is building a second growth pillar. Sales reached $166M in the preceding quarter, up 72% sequentially, and Gilead raised its 2026 Yeztugo guidance to $1B.
Gilead raised its 2026 HIV sales growth outlook to approximately 8% from 6% previously. The forecast includes roughly 2% of headwinds from lower Medicaid pricing and proposed Affordable Care Act changes.
Trodelvy continued to expand, with preceding-quarter sales of $402M, up 37% year over year and 5% sequentially. Cell therapy sales moved in the opposite direction, falling 12% year over year to $407M.
Analyst sentiment remains constructive but divided. The consensus rating is Buy, with 39 buys, 18 holds and one sell. Cantor Fitzgerald maintained Overweight with a $155 price target, while Leerink Partners moved to Market Perform with a $127 target.
Gilead Sciences, Inc. Earnings Analysis: Financial Performance
The headline GILD earnings result was a beat, but the income statement requires careful reading. Revenue of $7.80B rose from $6.96B in the March quarter and stood below the $7.92B reported for the December quarter. It also exceeded the $7.77B recorded in September and the $7.08B recorded in June 2025.
The quarterly financial data lists a net loss of $10.50B for the June 30 period. That figure sits beside headline EPS of -$6.75, which beat the -$7.26 estimate. Gilead's earnings history shows positive EPS in each of the four preceding entries: $2.03, $1.86, $2.47 and $2.01. The sharp shift into a reported loss makes acquisition accounting a central part of the financial story.
Gilead's first-quarter prepared remarks identified $11.5B in upfront payments tied to Arcellx, Ouro Medicines and Tubulis for recognition in the second quarter. Those transactions provide important context for the large loss line and explain why investors need to separate operating momentum from acquisition-related charges and financing costs.
The detailed segment figures from the preceding quarter show where the operating strength sits. HIV sales reached $5.0B, up 10% year over year. Biktarvy generated $3.4B, up 7%, while Descovy produced $807M, up 38%. The U.S. PrEP business grew approximately 50% year over year within Descovy's portfolio.
Yeztugo supplied the most striking launch data. Sales increased 72% sequentially to $166M. Gilead reported U.S. coverage at approximately 95%, with 95% of covered individuals able to access the product with a $0 co-pay. Management also described Yeztugo as the leading long-acting injectable in the switch segment.
Outside HIV, Trodelvy sales of $402M offered a strong contribution. Livdelzi sales reached $133M and more than tripled year over year. By contrast, liver disease sales totaled $767M, up 1%, while cell therapy sales fell to $407M amid competition across regions.
Margins cannot be assessed from the reported figures here, but the cost structure already showed pressure in the preceding quarter. SG&A rose 12% year over year to $1.363B, with Gilead attributing the increase to higher selling and marketing expenses linked to the Yeztugo launch. The spending reflects a deliberate effort to turn HIV prevention into a larger commercial franchise.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Market Reaction and Analyst Response to GILD Earnings
GILD shares finished at $135.25, up 3.13%, at the latest regular-session close. Volume of 10,078,462 shares exceeded the 7,612,335 average. The price move shows that investors rewarded the revenue beat and the growth profile, even as the loss figure creates a less tidy earnings headline.
The analyst record points to a market weighing near-term execution against valuation and acquisition risk. Cantor Fitzgerald reiterated Overweight with a $155 price target on Aug. 4. The firm cited expectations for a Yeztugo revenue beat, making the product a direct driver of its positive stance.
Morgan Stanley maintained Overweight but lowered its price target to $168 from $175 in a note tied to Gilead's guidance update. The action kept a bullish rating while applying a more cautious valuation framework.
Leerink Partners supplied the clearest bearish counterpoint. On July 21, the firm downgraded GILD to Market Perform from Outperform and cut its price target to $127 from $146. That target sits below the latest $135.25 close, reflecting concern that the stock's pipeline value and acquisition spending already carry a high burden of proof.
HSBC took the opposite path on July 6, upgrading GILD to Buy from its prior stance and raising the price target to $155 from $133. HSBC cited Yeztugo, anito-cel and Trodelvy as important parts of the growth case. The overall consensus remains Buy, although the 39-to-18 split between buy and hold ratings shows that enthusiasm is not universal.
Management Commentary: The Strategic Case for Durable Growth
Our strong financial performance and increase in sales guidance reflects the depth and quality of our portfolio, the numerous launches underway and our continued focus on financial discipline. - Daniel O'Day, CEO, Earnings Call
O'Day's strategy rests on extending Gilead's HIV leadership while adding growth through prevention, oncology and cell therapy. He cited no major HIV loss-of-exclusivity events until 2036 and identified up to seven potential new HIV product launches by 2033.
With no major LOEs until 2036, Gilead's HIV business is poised for strong durable growth, supported by up to 7 potential new HIV product launches by 2033. - Daniel O'Day, CEO, Earnings Call
The pipeline timeline gives the current result a longer horizon. Gilead expects an FDA decision on bictegravir plus lenacapavir in August, while the PDUFA date for anito-cel is in December. The company expects anito-cel revenue to begin in early 2027 after site activation.
The financial guidance reinforces that strategy. Gilead lifted 2026 HIV sales growth to approximately 8% from 6% and set Yeztugo guidance at $1B. Those figures give investors measurable milestones for judging whether the launch investment is converting into durable cash flow.
Gilead's earnings beat strengthens the operating case, led by HIV growth, Yeztugo adoption and Trodelvy momentum. However, the $10.50B net loss and $11.5B of acquisition-related upfront payments keep accounting noise firmly in the picture.
For investors, the central test is execution: Yeztugo must support the $1B 2026 target, while anito-cel and Trodelvy must turn pipeline spending into future revenue. The Buy consensus and positive share reaction favor the growth thesis, but Leerink's downgrade shows that valuation discipline still matters.
+Did Gilead Sciences (GILD) beat earnings expectations this quarter?
Yes. Gilead reported EPS of -$6.75 versus an estimated -$7.26 and revenue of $7.80 billion versus the $7.40 billion consensus. The stock rose 3.13% to $135.25 on the news.
+Why did GILD report a large quarterly loss even though it beat estimates?
The reported net loss of $10.50 billion was driven by acquisition accounting and related charges, not just operating performance. Gilead said $11.5 billion in upfront payments tied to Arcellx, Ouro Medicines, and Tubulis would be recognized in the quarter.
+What is driving Gilead Sciences' growth right now?
HIV is still the main growth engine, with the prior quarter's HIV sales up 10% year over year to $5.0 billion. Yeztugo is emerging as a second pillar, with sales of $166 million, up 72% sequentially, and Gilead raised its 2026 Yeztugo guidance to $1 billion.
+How are analysts viewing GILD after the earnings report?
Sentiment remains constructive but mixed, with a consensus Buy rating from 39 buys, 18 holds, and one sell. Cantor Fitzgerald kept an Overweight rating with a $155 target, while Leerink Partners downgraded the stock to Market Perform with a $127 target.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on GILD?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
